Instrument Inactif

Communiqués Celsion Corporation Nasdaq

Actions

US15117N4043

Recherche biotechnologique et médicale

Cours en clôture Nasdaq Autres places de cotation
- ^USD	-

30/06	Imunon, Inc. nomme Josh Blacher aux postes de responsable financier et responsable comptable, avec effet au 1er juillet 2026	CI
23/06	IMUNON Inc. poursuit l’essai clinique pivot de phase 3 OVATION 3 sur IMNN-001 en association avec la chimiothérapie standard	CI

Communiqués

23/06	IMUNON Announces Data Monitoring Committee Recommends Continuation of Phase 3 OVATION 3 Study Without Modification	AQ
22/06	IMUNON to Present at the Life Sciences Investor Forum on June 25th	AQ
04/06	IMUNON Announces Up to $10 Million Cash Financing	AQ
12/05	IMUNON Reports First Quarter 2026 Financial Results and Provides Business Update	AQ
05/05	IMUNON to Hold First Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, May 12, 2026	AQ
31/03	IMUNON Reports 2025 Financial Results and Provides Business Update Highlighting Significant Progress with Pivotal Phase 3 Study	AQ
25/03	IMUNON Reports Updated Phase 2 Data Showing Continued Improvement in Median Overall Survival with IMNN-001 in Women with Newly Diagnosed Advanced Ovarian Cancer	AQ
24/03	IMUNON to Hold 2025 Financial Results and Business Update Conference Call on Tuesday, March 31, 2026	AQ
05/02	IMUNON SHARPENS FOCUS ON ITS PROMISING PIVOTAL PHASE 3 OVARIAN CANCER STUDY	AQ
30/12	IMUNON Announces Pricing of $7.0 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules	AQ
29/12	IMUNON 2025, A TRANSFORMATIVE YEAR OF SIGNIFICANT CLINICAL ADVANCES, LOOKING AHEAD TO 2026	AQ
13/11	IMUNON Reports Third Quarter 2025 Financial Results and Provides Business Update	AQ
10/11	IMUNON Public Webcast Highlights Resilience and Innovation in Pursuit of the First Approved Immunotherapy for Ovarian Cancer	AQ
10/11	IMUNON : R&D Day Highlighting Progress on OVATION 3 Study	PU
10/11	IMUNON R&D Day Showcases Clinical Progress of Its Novel Immunotherapy, Phase 3 Trial and Significant Potential for Women with Ovarian Cancer	AQ
07/11	IMUNON R&D Day: Opportunity to Hear Clinical Trial Investigators Discuss Significant Potential of IMNN-001 to Redefine Ovarian Cancer Treatment	AQ
06/11	IMUNON to Hold Third Quarter 2025 Financial Results and Business Update Conference Call on Thursday, November 13, 2025	AQ
04/11	IMUNON Announces Webcast of In-Person R&D Day Highlighting Progress on OVATION 3 Study in Pursuit of First Frontline Immunotherapy for Advanced Ovarian Cancer	AQ
30/10/25	IMUNON to Present Phase 3 OVATION 3 Study of IMNN-001 in Advanced Ovarian Cancer at IGCS 2025 Annual Global Meeting	AQ
23/10/25	IMUNON to Present New Translational Data from Phase 2 OVATION 2 Study of IMNN-001 at SITC 40th Annual Meeting	AQ
20/10/25	IMUNON Hosts R&D Day Highlighting Progress on OVATION 3 Study in Pursuit of First Frontline Immunotherapy for Advanced Ovarian Cancer	AQ
17/10/25	IMUNON Invited to Present PlaCCine® DNA Technology Proof-of-Concept Data in Platform Presentations at Leading Vaccine Conferences	AQ
14/10/25	IMUNON to Present Phase 3 Ovarian Cancer Study of IMNN-001 at ESMO Congress	AQ
22/09/25	IMUNON to Present New Translational Data of IMNN-001 Supporting Phase 3 Trial of Immunotherapy for Ovarian Cancer at AACR Special Conference in Cancer Research	AQ
22/09/25	Imunon : Presentation AACR Special Conference in Cancer Research	PU